Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics

Authors:

Abstract
To explore the feasibility of using amide proton transfer-weighted (APTw) MRI metrics as surrogate biomarkers to identify the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status in glioblastoma (GBM).
Funding Information
  • National Natural Science Foundation of China (81171322)
  • National Institute of Biomedical Imaging and Bioengineering (R01EB009731)
  • National Cancer Institute (R01CA166171)

This publication has 67 references indexed in Scilit: